Homayounfar, Kia

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ruehlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T09:34:12Z"],["dc.date.available","2018-11-07T09:34:12Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900255"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32127"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.title","SRC expression in locally advanced rectal cancer-before and after neoadjuvant chemoradiotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","550"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","British Journal of Surgery"],["dc.bibliographiccitation.lastpage","557"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Helms, H.-J."],["dc.contributor.author","Lordick, Florian"],["dc.contributor.author","Rueschoff, Josef"],["dc.contributor.author","Conradi, L.-C."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Thorsten"],["dc.date.accessioned","2018-11-07T09:41:56Z"],["dc.date.available","2018-11-07T09:41:56Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Multidisciplinary discussion of the treatment of patients with colorectal liver metastases (CRLM) is advocated currently. The aim of this study was to investigate medical oncologists' and surgeons' assessment of resectability and indication for chemotherapy, and the effect of an educational intervention on such assessment. Methods: Medical histories of 30 patients with CRLM were presented to ten experienced medical oncologists and 11 surgeons at an initial virtual tumour board meeting (TB1). Treatment recommendations were obtained from each participant by voting for standardized answers. Following lectures on the potential of chemotherapy and surgery, assessment was repeated at a second virtual tumour board meeting (TB2), using the same patients and participants. Results: Overall, 630 answers (21 x 30) were obtained per tumour board meeting. At TB1, resectability was expected more frequently by surgeons. Participants changed 56.8 per cent of their individual answers at TB2. Assessment shifted from potentially resectable to resectable CRLM in 81 of 161 and from unresectable to (potentially) resectable CRLM in 29 of 36 answers. Preoperative chemotherapy was indicated more often by medical oncologists, and overall was included in 260 answers (41.3 per cent) at TB1, compared with only 171 answers (27.1 per cent) at TB2. Medical oncologists more often changed their decision to primary resection in resectable patients (P = 0.006). Postoperative chemotherapy was included in 51.9 and 52.4 per cent of all answers at TB1 and TB2 respectively, with no difference in changes between medical oncologists and surgeons (P = 0.980). Conclusion: Resectability and indication for preoperative chemotherapy were assessed differently by medical oncologists and surgeons. The educational intervention resulted in more patients deemed resectable by both oncologists and surgeons, and less frequent indication for chemotherapy."],["dc.description.sponsorship","Merck Serono GmbH, Germany"],["dc.identifier.doi","10.1002/bjs.9436"],["dc.identifier.isi","000332700100017"],["dc.identifier.pmid","24756914"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33842"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1365-2168"],["dc.relation.issn","0007-1323"],["dc.title","Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","292"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","VISZERALCHIRURGIE"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Schuetze, Gunther"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.date.accessioned","2018-11-07T10:58:26Z"],["dc.date.available","2018-11-07T10:58:26Z"],["dc.date.issued","2007"],["dc.description.abstract","40 % of patients suffering from colorectal cancer will develop liver metastases during the course of their disease. Advances in both surgical technique and perioperative management lead to a decrease in postoperative morbidity and mortality. Against the background of an increasing understanding of tumor biology as well as excellent survival data following hepatic resection, the indication for liver resection has been extended in specialized surgical centers. Similarly the intention to treat changed from a standardized resection towards an individual and interdisciplinary therapy including preoperative chemotherapy, staged liver resection and resection of extrahepatic disease. The aim of this study is to investigate the current value of hepatic resection for colorectal liver metastases in the interdisciplinary oncological concept. It specially addresses these challenging situations where palliative chemotherapy seemed to be the only reasonable way of therapy in past."],["dc.identifier.doi","10.1055/s-2007-981332"],["dc.identifier.isi","000254585100003"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50476"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1435-3067"],["dc.title","Surgical therapy for colorectal liver metastases: Prospects and limits"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:45:05Z"],["dc.date.available","2018-11-07T09:45:05Z"],["dc.date.issued","2014"],["dc.identifier.isi","000333682100536"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34538"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Gastrointestinal Cancers Symposium"],["dc.relation.eventlocation","San Francisco, CA"],["dc.title","Residual rectal cancer after preoperative radiochemotherapy (ypT1-2): An indication for local excision instead of radical surgery?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","09"],["dc.bibliographiccitation.journal","Zeitschrift für Gastroenterologie"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Becker, H"],["dc.contributor.author","Langer, C"],["dc.date.accessioned","2019-11-26T13:22:46Z"],["dc.date.available","2019-11-26T13:22:46Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1055/s-0028-1089657"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62675"],["dc.language.iso","de"],["dc.relation.issn","0044-2771"],["dc.relation.issn","1439-7803"],["dc.title","Kolorektale Lebermetastasen: hat der Zeitpunkt des Auftretens eine Bedeutung für das onkologische Konzept und die Prognose?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1283"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","American Journal of Surgical Pathology"],["dc.bibliographiccitation.lastpage","1289"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Gauss, Korbinian"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Scheel, Andreas H."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2021-06-01T10:47:01Z"],["dc.date.available","2021-06-01T10:47:01Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1097/PAS.0b013e3182886ced"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85449"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0147-5185"],["dc.title","Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy"],["dc.title.alternative","Impact of Intramesorectal Distribution and Residual Micrometastatic Involvement"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","435"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","435 Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of 3/ 3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.435"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S430"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H.A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71771-3"],["dc.identifier.pii","S0959804911717713"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110450"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6126 POSTER Thymidylate Synthase as Biomarker in Rectal Cancer Patients After 5-FU-based Radiochemotherapy – Evaluation of the Prognostic Capacity in Pre-treatment Biopsies and Resected Adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","638"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","649"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:27:25Z"],["dc.date.available","2018-11-07T10:27:25Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) I-131-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m(2) per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were \"truly adjuvant.\" Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as \"possibly nonadjuvant,\" but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N=5) or relapse (N=14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The \"truly adjuvant\" patients (N=39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P<.001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P=.014), and CSS (not reached vs 41.4 months; hazard ratio, 0.42; P=.014) compared with \" possibly nonadjuvant\" patients (N=24). CONCLUSIONS: Repeated RIT with I-131-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for \"truly adjuvant\" patients. However, the maximum safe dose of I-131-labetuzumab is a single administration of 50 millicuries/m(2). (C) 2016 American Cancer Society."],["dc.description.sponsorship","University Medical Center Goettingen"],["dc.identifier.doi","10.1002/cncr.30390"],["dc.identifier.isi","000396841300015"],["dc.identifier.pmid","27763687"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43229"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.title","Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, H."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:19:02Z"],["dc.date.available","2018-11-07T09:19:02Z"],["dc.date.issued","2013"],["dc.format.extent","73"],["dc.identifier.isi","000326360900167"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28546"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0240"],["dc.relation.issn","0378-584X"],["dc.title","5-FU dose monitoring under neoadjuvant radiochemotherapy and adjuvant chemotherapy for locally advanced rectal cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]